A multiple sclerosis (MS) patient treated in Germany with Ocrevus (ocrelizumab) has developed the dreaded brain infection progressive multifocal leukoencephalopathy (PML). But…
Fampyra (prolonged-release fampridine tablets) — sold in the U.S. as Ampyra (dalfampridine) — has now been granted standard marketing authorization…
May 31 is World MS Day. In its honor, Teva Pharmaceuticals Europe has launched “Life Moments with MS” —…
Healthline recently selected Multiple Sclerosis News Today as one of the Best Multiple Sclerosis Blogs of 2017, spotlighting its columns…
MS brain inflammation is a result of interactions between processes in the brain and the rest of the body, with…
Multiple sclerosis (MS) patients are largely moving away from injectable drugs and towards oral treatments when they switch from first…
A study of nearly 600 children with multiple sclerosis reported that genes linked to low vitamin D levels and obesity contribute…
The online BrainHQ adaptive training program developed by Posit Science is better than any computer game at helping multiple sclerosis (MS)…
What makes housing accessible? I thought I knew all of the features that would make a dwelling accessible.
Two studies that recently appeared in the Multiple Sclerosis Journal shed light on how contraceptive use may affect women with MS, as…
Former Massachusetts First Lady Ann Romney, global ambassador for Boston’s Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, will…
Recently approved, Ocrevus (ocrelizumab) should now be available nationwide for patients prescribed the therapy. But as with any…
The National Multiple Sclerosis Society is pumping $17 million into 43 research projects that represent almost half of its $40-million research funding…
A global Phase 3 clinical trial assessing MD1003 — also known as high-dose biotin — for progressive multiple sclerosis (MS)…
People with multiple sclerosis (MS) and others with spinal cord injuries and disorders will speak at the United Spinal Association’s upcoming…
I now introduce myself as a disability rights activist. I began to pay attention to local politics and…
A multiple sclerosis (MS) trial now underway in Colorado is assessing the safety and tolerability of switching from Rituxan (rituximab) to …
Axim Biotechnologies recently announced that its U.K. partner, Quay Pharmaceuticals, has secured licenses from the British Home Office…
Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet…
A significant percentage of multiple sclerosis (MS) patients struggle with improper diagnoses and ineffective treatments, a national survey of more…
Lemtrada (alemtuzumab) may be more effective in preventing relapses in multiple sclerosis patients than the newly approved Ocrevus…
Within the first two months of treatment, Ocrevus (ocrelizumab) reduced relapses in multiple sclerosis (MS) patients by more than…
Real-world data of treatment with Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) in relapsing multiple sclerosis (MS) patients suggest that treatment…
A real-world study of Gilenya (fingolimod) in relapsing multiple sclerosis (MS) confirms benefits of the treatment seen in clinical trials.
An investigational treatment called ATA188 that wipes out B-cells targeting the Epstein-Barr virus (EBV) has shown promise as a multiple…
Multiple sclerosis causes debilitating fatigue. The following photographs show, without censorship, what my fatigue leaves undone. The homes of…
A combination of mutations in two genes makes members of a Canadian family a 7-in-10 chance of developing multiple sclerosis…
New data on the recently approved multiple sclerosis (MS) drug Ocrevus (ocrelizumab) will be presented at the upcoming…
While many multiple sclerosis patients celebrated the recent approval of Ocrevus (ocrelizumab), others argued that the drug is largely a rebranded…
The Blair Chiropractic Technique may ease multiple sclerosis (MS) symptoms, studies indicate. The technique involves adjusting the spinal column’s upper…
Get regular updates to your inbox.
